Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
In a historic first, the FDA clears DemeRx's noribogaine hydrochloride for Phase I study, marking the first US clinical trial of an ibogaine-derived compound for addiction treatment.
Tens of thousands of individuals harmed by OxyContin will receive nothing from Purdue's $7.4 billion bankruptcy settlement after strict eligibility changes and documentation requirements.
State Department deploys economic sanctions against sophisticated supply chain providing precursor chemicals to Sinaloa Cartel, implementing Executive Order designating fentanyl as Weapon of Mass Destruction.
Leaked details reveal DEA plans to limit telehealth prescriptions for controlled substances, requiring 50% in-person visits and affecting buprenorphine access for opioid use disorder treatment.
Study of 600,000 U.S. veterans finds GLP-1 drugs like Ozempic and Wegovy associated with dramatic reductions in substance use disorder complications, overdoses, and deaths.
White House drug policy leaders meet with DHS, DOJ, and intelligence agencies to align operations against fentanyl trafficking and sign updated committee charter.
New research reveals 20% of U.S. pharmacies refuse to dispense buprenorphine, creating critical barriers to opioid addiction treatment despite federal expansion efforts.
New Jersey will receive $1.1 billion through 2038 from opioid settlements, with funds split between state programs and 262 local governments.
President Trump signed an executive order accelerating psychedelic drug research, directing FDA priority vouchers, Right to Try access, and $50 million in federal-state partnerships.